Spruce Biosciences, Inc. (SPRB) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-09

How it makes money

It currently earns nothing and expects patients to pay for its future therapy.

The company is a pre-revenue biopharmaceutical firm. It intends to earn money by selling tralesinidase alfa enzyme replacement therapy (TA-ERT), a treatment for Sanfilippo Syndrome Type B, to patients and payers.

Profit will be driven by the ability to obtain regulatory approval and the total addressable patient market.

What protects it: the moat

It relies on regulatory designations and licensed intellectual property.

The company uses Orphan Drug and Breakthrough Therapy designations to gain advantages in the regulatory process and market exclusivity. It also depends on intellectual property licensed from third parties to prevent competitors from replicating its therapy.

What growth costs

It must invest in clinical trials and build a commercial organization.

The company has no maintenance costs for existing products. Growth requires funding a confirmatory study for TA-ERT, expanding manufacturing capacity to meet global demand, and hiring a specialized sales force to launch the therapy.

What could damage it

Failure to obtain regulatory approval for TA-ERT would eliminate its only commercial path.

Because the company has shifted its focus primarily to TA-ERT, a failure in clinical trials or a rejection by the FDA would leave it without a commercial product, rendering its current investments futile.

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Other companies in Biotechnology